MOTS-c Peptide Investigated for Insulin Sensitivity in Prediabetes and Obesity
Background
Prediabetes and obesity are significant global health challenges, often leading to insulin resistance and increasing the risk of developing type 2 diabetes. Current treatments often focus on lifestyle changes and existing medications, but novel therapeutic approaches are needed. This study aims to evaluate if the mitochondrial-derived peptide MOTS-c can improve insulin sensitivity in adults with prediabetes and overweight/obesity.
Results
This study is currently recruiting and therefore has no results to report yet. However, the primary objective is to evaluate whether 12 weeks of MOTS-c treatment significantly improves insulin sensitivity compared to placebo. The study will specifically assess changes in insulin sensitivity using established metrics, expecting to observe a statistically significant improvement in the MOTS-c group. Researchers will also investigate secondary endpoints such as changes in HbA1c, body weight, body composition, and other metabolic markers, looking for favorable shifts in these parameters. The goal is to identify quantitative differences between the MOTS-c and placebo groups across these measures, with a focus on safety and tolerability.
Why It Matters
MOTS-c is a novel mitochondrial-derived peptide with potential roles in metabolic regulation, including glucose homeostasis. If this Phase 2a study demonstrates significant improvements in insulin sensitivity and a favorable safety profile, it could pave the way for MOTS-c as a new therapeutic option for prediabetes and obesity. Positive results would support advancing MOTS-c to larger Phase 2b and Phase 3 human trials, potentially offering a new mechanism to combat metabolic dysfunction and prevent progression to type 2 diabetes.